These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 25637055)

  • 1. GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6.
    Rasche L; Duell J; Castro IC; Dubljevic V; Chatterjee M; Knop S; Hensel F; Rosenwald A; Einsele H; Topp MS; Brändlein S
    Haematologica; 2015 Mar; 100(3):377-84. PubMed ID: 25637055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement.
    Rasche L; Menoret E; Dubljevic V; Menu E; Vanderkerken K; Lapa C; Steinbrunn T; Chatterjee M; Knop S; Düll J; Greenwood DL; Hensel F; Rosenwald A; Einsele H; Brändlein S
    Clin Cancer Res; 2016 Sep; 22(17):4341-9. PubMed ID: 27029491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The natural human IgM antibody PAT-SM6 induces apoptosis in primary human multiple myeloma cells by targeting heat shock protein GRP78.
    Rasche L; Duell J; Morgner C; Chatterjee M; Hensel F; Rosenwald A; Einsele H; Topp MS; Brändlein S
    PLoS One; 2013; 8(5):e63414. PubMed ID: 23667612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early development of PAT-SM6 for the treatment of melanoma.
    Hensel F; Eckstein M; Rosenwald A; Brändlein S
    Melanoma Res; 2013 Aug; 23(4):264-75. PubMed ID: 23728394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The anti-cancer IgM monoclonal antibody PAT-SM6 binds with high avidity to the unfolded protein response regulator GRP78.
    Rosenes Z; Mulhern TD; Hatters DM; Ilag LL; Power BE; Hosking C; Hensel F; Howlett GJ; Mok YF
    PLoS One; 2012; 7(9):e44927. PubMed ID: 23028685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma.
    Hansson M; Gimsing P; Badros A; Niskanen TM; Nahi H; Offner F; Salomo M; Sonesson E; Mau-Sorensen M; Stenberg Y; Sundberg A; Teige I; Van Droogenbroeck J; Wichert S; Zangari M; Frendeus B; Korsgren M; Poelman M; Tricot G
    Clin Cancer Res; 2015 Jun; 21(12):2730-6. PubMed ID: 25712687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.
    Lokhorst HM; Plesner T; Laubach JP; Nahi H; Gimsing P; Hansson M; Minnema MC; Lassen U; Krejcik J; Palumbo A; van de Donk NW; Ahmadi T; Khan I; Uhlar CM; Wang J; Sasser AK; Losic N; Lisby S; Basse L; Brun N; Richardson PG
    N Engl J Med; 2015 Sep; 373(13):1207-19. PubMed ID: 26308596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.
    Benson DM; Cohen AD; Jagannath S; Munshi NC; Spitzer G; Hofmeister CC; Efebera YA; Andre P; Zerbib R; Caligiuri MA
    Clin Cancer Res; 2015 Sep; 21(18):4055-61. PubMed ID: 25999435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma.
    Papadopoulos KP; Siegel DS; Vesole DH; Lee P; Rosen ST; Zojwalla N; Holahan JR; Lee S; Wang Z; Badros A
    J Clin Oncol; 2015 Mar; 33(7):732-9. PubMed ID: 25225420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.
    Ghobrial IM; Weller E; Vij R; Munshi NC; Banwait R; Bagshaw M; Schlossman R; Leduc R; Chuma S; Kunsman J; Laubach J; Jakubowiak AJ; Maiso P; Roccaro A; Armand P; Dollard A; Warren D; Harris B; Poon T; Sam A; Rodig S; Anderson KC; Richardson PG
    Lancet Oncol; 2011 Mar; 12(3):263-72. PubMed ID: 21345726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous binding of the anti-cancer IgM monoclonal antibody PAT-SM6 to low density lipoproteins and GRP78.
    Rosenes Z; Mok YF; Yang S; Griffin MD; Mulhern TD; Hatters DM; Hensel F; Howlett GJ
    PLoS One; 2013; 8(4):e61239. PubMed ID: 23620733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma.
    Tai YT; Li X; Tong X; Santos D; Otsuki T; Catley L; Tournilhac O; Podar K; Hideshima T; Schlossman R; Richardson P; Munshi NC; Luqman M; Anderson KC
    Cancer Res; 2005 Jul; 65(13):5898-906. PubMed ID: 15994968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma.
    Kaufman JL; Niesvizky R; Stadtmauer EA; Chanan-Khan A; Siegel D; Horne H; Wegener WA; Goldenberg DM
    Br J Haematol; 2013 Nov; 163(4):478-86. PubMed ID: 24112026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.
    Maloney DG; Grillo-López AJ; Bodkin DJ; White CA; Liles TM; Royston I; Varns C; Rosenberg J; Levy R
    J Clin Oncol; 1997 Oct; 15(10):3266-74. PubMed ID: 9336364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma.
    Benson DM; Hofmeister CC; Padmanabhan S; Suvannasankha A; Jagannath S; Abonour R; Bakan C; Andre P; Efebera Y; Tiollier J; Caligiuri MA; Farag SS
    Blood; 2012 Nov; 120(22):4324-33. PubMed ID: 23033266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma.
    Bensinger W; Maziarz RT; Jagannath S; Spencer A; Durrant S; Becker PS; Ewald B; Bilic S; Rediske J; Baeck J; Stadtmauer EA
    Br J Haematol; 2012 Oct; 159(1):58-66. PubMed ID: 22861192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.
    Alsina M; Trudel S; Furman RR; Rosen PJ; O'Connor OA; Comenzo RL; Wong A; Kunkel LA; Molineaux CJ; Goy A
    Clin Cancer Res; 2012 Sep; 18(17):4830-40. PubMed ID: 22761464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma.
    Dunn TJ; Dinner S; Price E; Coutré SE; Gotlib J; Hao Y; Berube C; Medeiros BC; Liedtke M
    Br J Haematol; 2016 Apr; 173(2):253-9. PubMed ID: 27040320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined phase I/II study of imexon (AOP99.0001) for treatment of relapsed or refractory multiple myeloma.
    Moehler TM; Feneberg R; Ho AD; Golenkov AK; Ludwig H; Kropff M; Khuageva NK; Hajda J; von Broen I; Goldschmidt H
    Anticancer Drugs; 2010 Aug; 21(7):708-15. PubMed ID: 20571355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.